Cancer Researchers to Use Biometric Wearables in New Study -

BioIntelliSense’s wearable BioSticker will soon be used to gather data in clinical trials with cancer patients. To that end, the company has formed a strategic partnership with The Leukemia & Lymphoma Society (LLS), which will be using the stickers to monitor the vital signs of the hematological cancer patients in the study.

The BioIntelliSense BioSticker is an FDA-approved single-use device that can be worn on the body for a period of up to 30 days. The data collected with the device can be consolidated and analyzed using the company’s Data-as-a-Service platform, which will also be provided to LLS through the new strategic partnership.

LLS will use the data generated with the BioSticker to gauge the effectiveness of different treatments, linking those treatments to a patient’s symptoms to see how well they respond. The BioSticker is able to track a number of different metrics, including body temperature, heart rate, respiration, and body position.

“Our medical grade devices and data services can have a profound impact on oncology care by unlocking unique and actionable clinical intelligence to guide treatment decisions,” said BioIntelliSense CEO James Mault. “We are extremely proud to be partnering with The Leukemia & Lymphoma Society as a global leader in blood cancer research and support services.”

The BioSticker received FDA approval and was cleared for commercial launch in January of 2020, shortly ahead of the international spread of COVID-19. The pandemic generated much more interest in remote patient monitoring solutions that can provide doctors with accurate medical data while minimizing the need for in-person contact.

BioIntelliSense has since supplemented the BioSticker with the release of a 5G BioHub that will automatically consolidate patient data and upload that data to the cloud. The company also updated its Data-as-a-Service platform to better track common symptoms like sneezing and coughing in real time.

–

(Originally posted on Mobile ID World)

Related News

Sponsored Links

TECH5 is an international technology company founded by experts from the biometrics industry, which focuses on developing disruptive biometric and digital ID solutions through the application of AI and Machine Learning technologies.

TECH5 target markets include both Government and Private sectors with products powering Civil ID, Digital ID, as well as authentication solutions that deliver identity assurance for various use cases.

Learn more: www.tech5.ai

Onfido is building the new identity standard for the internet.Our AI-based technology assesses whether a user’s government-issued ID is genuine or fraudulent, and then compares it against their facial biometrics. That’s how we give companies like Revolut, Zipcar and Bitstamp the assurance they need to onboard customers remotely and securely. Our mission is to create a more open world, where identity is the key to access.. For more information, please visit www.onfido.com

ThreatMark brings trust to the digital world by providing cutting-edge fraud prevention solutions. Major banks use ThreatMark’s AI-powered technology and behavioral biometrics to build secured banking experience to precisely verify their legitimate users, seamlessly across all digital channels. All while securing the users’ most precious assets and keeping the fraudsters away. Learn more: www.threatmark.com/

With its secunet border gears product portfolio and specialised consulting expertise, secunet supports police forces and security authorities in their sovereign tasks. Whether ABC gates, self-service kiosks or biometric middleware – each component helps to strengthen identity protection and to accelerate verification – in mobile and stationary scenarios.

Mobile ID World is here to bring you the latest in mobile authentication solutions and application providers. Our company is dedicated to providing users with the best content and cutting edge information on technology, news, and mobile solutions for your mobile identity management needs.

Related News

Footer

Follow Us